5 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 5 of 5 clinical reviews.
Deep dive into the FREEDOM trial extension: 10-year denosumab durability data, rebound vertebral fractures after discontinuation, and long-term safety signals including ONJ and atypical femoral fractures.
A deep dive into the FREEDOM trial's primary and secondary endpoint data for denosumab in postmenopausal osteoporosis, including effect sizes, confidence intervals, subgroup analyses, and the time-course pattern of fracture reduction.
FREEDOM trial: denosumab cut vertebral fractures 68%, hip fractures 40%, nonvertebral fractures 20% over 3 years in 7,868 postmenopausal women.
A detailed methodology breakdown of the FREEDOM trial (denosumab vs placebo for postmenopausal osteoporosis), covering randomization, blinding, endpoint definitions, statistical design, and how each choice shapes clinical interpretation.
How the FREEDOM trial reshaped osteoporosis treatment guidelines, shifted prescribing patterns for denosumab, and what clinicians should consider for patients outside the original study population.